ENDRA Life Sciences (NDRA) Long-Term Deferred Tax (2016 - 2024)

ENDRA Life Sciences (NDRA) has reported Long-Term Deferred Tax for 9 consecutive years, with $24.6 million the latest figure, recorded in Q4 2024.

• On a quarterly basis, Long-Term Deferred Tax rose 16.12% year-over-year to $24.6 million in Q4 2024; TTM through Dec 2024 was $24.6 million, a 16.12% increase from a year earlier, with the FY2024 full-year figure at $24.6 million, up 16.12% from the prior year.
• Long-Term Deferred Tax was $24.6 million for Q4 2024 at ENDRA Life Sciences, up from $21.2 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $24.6 million in Q4 2024 and troughed at $11.3 million in Q4 2020.
• A 5-year average of $17.9 million and a median of $18.5 million in 2022 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax soared 39.16% in 2020 and grew 14.2% in 2023, its largest moves.
• Over 5 years, Long-Term Deferred Tax stood at $11.3 million in 2020, then advanced by 25.88% to $14.2 million in 2021, then soared by 30.5% to $18.5 million in 2022, then climbed by 14.2% to $21.2 million in 2023, then rose by 16.12% to $24.6 million in 2024.
• The last three Long-Term Deferred Tax figures came in at $24.6 million (Q4 2024), $21.2 million (Q4 2023), and $18.5 million (Q4 2022), per Business Quant data.